Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer

Launched by UNIVERSITY HOSPITAL, GHENT · Nov 17, 2020

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for men with a specific type of prostate cancer called oligometastatic recurrent hormone-sensitive prostate cancer. The researchers want to find out if combining a medication called darolutamide with a type of radiation therapy known as Stereotactic Body Radiotherapy (SBRT) can help patients live longer without their cancer spreading, while also keeping their quality of life intact. The trial is currently recruiting male participants aged 18 and older who have been diagnosed with prostate cancer and experienced a recurrence after previous treatments.

To be eligible for this study, participants need to have a confirmed diagnosis of prostate cancer that has spread to a maximum of five areas in the body, identified through special imaging tests. They should also be in good overall health and not experiencing any significant symptoms from their cancer. Throughout the trial, participants will receive regular check-ups and care from the medical team, and they will be closely monitored to see how well the treatment works and if there are any side effects. This study is important because it aims to find better treatment options for men facing this challenging stage of prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Histologically proven initial diagnosis of adenocarcinoma of the prostate
• • Biochemical relapse of PCa following radical local prostate treatment (radical prostatectomy (RP), primary radiotherapy or the combination of RP and prostate bed adjuvant/ salvage radiotherapy) according to the EAU guidelines 2018.
• • Following RP, patients with a biochemical relapse are eligible in case a metastatic relapse is detected even in the absence of prior postoperative prostate bed radiotherapy (adjuvant or salvage). In the absence of prior prostate bed radiotherapy, prostate bed radiotherapy is mandatory for all pT3a or higher or patients with a positive margin at time of RP.
• • For patients without prior RP that have a suspected local recurrence following primary radiotherapy, a biopsy should confirm local recurrence. Patients with a confirmed local recurrence and metastases are eligible in case they also undergo a local salvage therapy.
• • Metastatic relapse on PSMA PET-CT with a maximum of 5 metastases (any M1a, M1b or M1c). Concomitant diagnosis of N1 disease is allowed as long as all lesions are treated with SBRT and the total number of lesions does not exceed 5. PSMA positive lesions will be scored using the MI-RADS scoring system with lesions scored 4 or 5 considered positive19.
• • Asymptomatic for metastatic PCa
• • Age \>= 18 years
• • WHO class 0-1
• • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
• • Before patient registration/randomization, written informed consent must be given in accordance with to ICH/GCP, and national/local regulations.
• Exclusion Criteria:
• • Local relapse in the prostate gland or prostate bed not suitable for a local salvage treatment
• • Small cell carcinoma of the prostate
• • PSA doubling time \>12 months
• • Serum testosterone level \<50ng/dl or 1.7 nmol/L at time of randomization
• • Currently receiving ADT or PSA rise while on active treatment with ADT (LHRH-agonist, LHRH-antagonist, anti-androgen or estrogen) within the past 6 weeks
• • Spinal cord compression or impending spinal cord compression
• • Metastases in previously irradiated areas precluding safe delivery of SBRT
• • Contraindications to darolutamide
• • Previous treatment with cytotoxic agent for PCa
• • Treatment during the past month with products known to influence PSA levels (e.g. fluconazole, finasteride, corticosteroids,...)
• • Other active malignancy, except non-melanoma skin cancer or other malignancies with a documented disease-free survival for a minimum of 3 years.